More efficient internalisation and release – not bystander activity – are the focus for this private ADC player.

An analysis of OncologyPipeline shows that $144bn has been pledged for ADCs since the start of 2022.

Competitors have given up on monotherapies in this use, but GenFleet wants to buck the trend.

The group reckons big pharma is eyeing KIF18A inhibition, but for now there are just a handful of players.

Blockade of CCR8 has quietly emerged as a hot oncology target, especially for anti-PD-(L)1 MAb combinations.

Despite a growing presence outside cancer, the company wants to stay true to its “DNA”.